Journal: Journal of Cancer

Article Title: TGF-?2: A Novel Target of CD44-Promoted Breast Cancer Invasion

doi: 10.7150/jca.6638

Figure Lengend Snippet: Time-course RT-PCR validation of TGF-beta2 as a potential target of CD44 in MCF7F-B5 breast cancer cell line . RNA samples were collected at different time points (18, 24 and 48hrs) following withdrawal of tet in the presence of hyaluronan (HA). The highly metastatic breast cancer cell line MDA-231 which expresses high levels of CD44 as well as TGF-beta2 was used as a positive control.

Article Snippet: Hyaluronan of molecular weight 220 kDa and medical grade purity was purchased from Lifecore Biomedical Inc. (Chaska, MN).

Techniques: Reverse Transcription Polymerase Chain Reaction, Multiple Displacement Amplification, Positive Control

Journal: Journal of Cancer

Article Title: TGF-?2: A Novel Target of CD44-Promoted Breast Cancer Invasion

doi: 10.7150/jca.6638

Figure Lengend Snippet: Time-course western-blot validation of the tetracycline (tet) regulated CD44 expression in MCF7F-B5 breast cancer cell line. Protein lysates were collected at different time points (18, 24 and 48hrs) following withdrawal of tet, in the presence of hyaluronan (HA). The level of expression of CD44s showed a time-dependent increase and was maintained up to 48 hrs.

Article Snippet: Hyaluronan of molecular weight 220 kDa and medical grade purity was purchased from Lifecore Biomedical Inc. (Chaska, MN).

Techniques: Western Blot, Expressing

Journal: Journal of Cancer

Article Title: TGF-?2: A Novel Target of CD44-Promoted Breast Cancer Invasion

doi: 10.7150/jca.6638

Figure Lengend Snippet: Time-course western blot validation of TGF-beta2 as a potential target of CD44 in MCF7F-B5 breast cancer cell line . Protein lysates were collected at different time points (18, 24 and 48hrs) following withdrawal of tet in the presence of hyaluronan (HA). The levels of expression of TGF-beta2 showed a time-dependent increase that was parallel to the increase of CD44 expression.

Article Snippet: Hyaluronan of molecular weight 220 kDa and medical grade purity was purchased from Lifecore Biomedical Inc. (Chaska, MN).

Techniques: Western Blot, Expressing

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Prefilled syringes and usability of ophthalmic viscosurgical devices

doi: 10.2147/OPTH.S67689

Figure Lengend Snippet: Investigational products. Notes: From the top, OPEGAN 1.1 mL, OPEGAN 0.6 mL, OPEGAN Hi 0.85 mL, Healon 0.85 mL.

Article Snippet: The major component of OPEGAN Hi® 0.85 mL (viscous cohesive; Seikagaku Corporation, Tokyo, Japan) and Healon® 0.85 mL (viscous cohesive; Abbott Medical Optics Inc, Santa Ana, CA, USA) has the same molecular weight.

Techniques:

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Prefilled syringes and usability of ophthalmic viscosurgical devices

doi: 10.2147/OPTH.S67689

Figure Lengend Snippet: Configuration of the Luer part (in order to enhance the visibility, the colored solution). Left: OPEGAN Hi 0.85 mL; right: Healon 0.85 mL.

Article Snippet: The major component of OPEGAN Hi® 0.85 mL (viscous cohesive; Seikagaku Corporation, Tokyo, Japan) and Healon® 0.85 mL (viscous cohesive; Abbott Medical Optics Inc, Santa Ana, CA, USA) has the same molecular weight.

Techniques:

Journal: The American Journal of Pathology

Article Title: Minocycline Attenuates Photoreceptor Degeneration in a Mouse Model of Subretinal Hemorrhage

doi: 10.1016/j.ajpath.2011.05.042

Figure Lengend Snippet: Photoreceptor apoptosis and microglial activation after subretinal hemorrhage. Experimental animals received subretinal injections of either blood or viscoelastic substance (0.5% sodium hyaluronate; control). Eyes were harvested for histopathologic analysis

Article Snippet: In control experiments, instead of autologous blood, 1.6 μL 0.5% sodium hyaluronate (Provisc; Alcon Laboratories, Inc., Fort Worth, TX) was injected in the contralateral eye using the same technique into the subretinal space.

Techniques: Activation Assay

Journal: Cancer Science

Article Title: Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors

doi: 10.1111/cas.13302

Figure Lengend Snippet: Growth delay curves and times of SCCVII tumors. (a) Effects of H 2 O 2 injection plus graded doses of irradiation. −, control (sodium hyaluronate); , H 2 O 2 with sodium hyaluronate; , sodium hyaluronate + 7 Gy; , H 2 O 2 with sodium hyaluronate + 7 Gy; , sodium hyaluronate + 14 Gy; , H 2 O 2 with sodium hyaluronate + 14 Gy; , sodium hyaluronate + 21 Gy; , H 2 O 2 with sodium hyaluronate + 21 Gy. (b ) Growth delay time as a function of radiation dose: , sodium hyaluronate + radiation; , H 2 O 2 with sodium hyaluronate + radiation. (c) Effects of H 2 O 2 injection plus fractionated irradiation. −, control (sodium hyaluronate); , H 2 O 2 with sodium hyaluronate; , sodium hyaluronate + 3 Gy × 5 times; , H 2 O 2 with sodium hyaluronate + 2 Gy × 5 times; , sodium hyaluronate + 4 Gy × 5 times; , H 2 O 2 with sodium hyaluronate + 3 Gy × 5 times; , sodium hyaluronate + 5 Gy × 5 times; , H 2 O 2 with sodium hyaluronate + 4 Gy × 5 times. All sodium hyaluronate with or without H 2 O 2 was injected three times on days 0, 2 and 4. All irradiation was delivered five times on days 0–4. (d) Growth delay time as a function of total radiation dose. , sodium hyaluronate injection + radiation; , H 2 O 2 with sodium hyaluronate injection + radiation. (a, c) Bars represent SE of 6 (non‐irradiated groups) or 12 mice (irradiated groups). (b, d) Bars represent SE . Curves were drawn by the quadratic polynomial approximate method.

Article Snippet: Tumor growth delay assay First, to investigate the effects of sodium hyaluronate and H2 O2 injection alone, 0.5 mL sodium hyaluronate with or without 0.5% w/v H2 O2 was administered intratumorally.

Techniques: Injection, Irradiation, Mouse Assay

Journal: Cancer Science

Article Title: Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors

doi: 10.1111/cas.13302

Figure Lengend Snippet: Immunofluorescent staining of SCCVII tumors at 60 min after intravenous pimonidazole administration. The blue areas represent tumors, and the green areas represent pimonidazole‐positive cells. (a) Control (sodium hyaluronate injection 15 min before pimonidazole). (b) H 2 O 2 with sodium hyaluronate injection 15 min before pimonidazole administration.

Article Snippet: Tumor growth delay assay First, to investigate the effects of sodium hyaluronate and H2 O2 injection alone, 0.5 mL sodium hyaluronate with or without 0.5% w/v H2 O2 was administered intratumorally.

Techniques: Staining, Injection

Journal: Cancer Science

Article Title: Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors

doi: 10.1111/cas.13302

Figure Lengend Snippet: Changes in the intratumoral distribution of oxygen bubbles over time after injection of sodium hyaluronate with or without H 2 O 2 . The mean values below the images represent the percentage of oxygen bubbles on CT slices of the maximum tumor size (three mice per group). Compared with the groups receiving H 2 O 2 immediately (1 min) before scanning, all the other groups had significantly smaller proportions of oxygen bubbles ( P

Article Snippet: Tumor growth delay assay First, to investigate the effects of sodium hyaluronate and H2 O2 injection alone, 0.5 mL sodium hyaluronate with or without 0.5% w/v H2 O2 was administered intratumorally.

Techniques: Injection, Mouse Assay

Journal: Cancer Science

Article Title: Biological effects of hydrogen peroxide administered intratumorally with or without irradiation in murine tumors

doi: 10.1111/cas.13302

Figure Lengend Snippet: Growth delay curves of SCCVII tumors. (a) Effects of sodium hyaluronate. ●, control (saline injection); , single sodium hyaluronate injection on day 0; , three sodium hyaluronate injections on days 0, 2 and 4; five sodium hyaluronate injections on days 0, 2, 4, 6 and 8. Bars represents SE of 12 mice. (b) Effects of H 2 O 2 . ●, control (sodium hyaluronate injection); H 2 O 2 with sodium hyaluronate, a single injection on day 0; , H 2 O 2 with sodium hyaluronate, three injections on days 0, 2 and 4; , H 2 O 2 with sodium hyaluronate, five injections on days 0, 2, 4, 6 and 8. Bars represents SE of 12 mice. (c) Influence of the interval between H 2 O 2 injection and irradiation. −, control (sodium hyaluronate); , H 2 O 2 with sodium hyaluronate; , sodium hyaluronate + 18 Gy; , H 2 O 2 with sodium hyaluronate + 18 Gy (1 min interval); , H 2 O 2 with sodium hyaluronate + 18 Gy (15 min); , H 2 O 2 with sodium hyaluronate + 18 Gy (30 min); , H 2 O 2 with sodium hyaluronate + 18 Gy (60 min); , H 2 O 2 with sodium hyaluronate + 18 Gy (120 min). Bars represent SE of 6 (non‐irradiated groups) or 12 mice (irradiated groups).

Article Snippet: Tumor growth delay assay First, to investigate the effects of sodium hyaluronate and H2 O2 injection alone, 0.5 mL sodium hyaluronate with or without 0.5% w/v H2 O2 was administered intratumorally.

Techniques: Injection, Mouse Assay, Irradiation

Journal: Endoscopy International Open

Article Title: A comparative study of grasping-type scissors forceps and insulated-tip knife for endoscopic submucosal dissection of early gastric cancer: a randomized controlled trial

doi: 10.1055/s-0042-105870

Figure Lengend Snippet: Chromoendoscopic observation: The depressed lesion (~10 mm diameter) in the antrum was assessed, and chromoendoscopy with indigo carmine was used to assess tumor extent and depth. b Marking: We made marking dots ~5 mm outside the tumor, with the tip of GSF using a forced coagulation mode. c Injection: We injected the submucosa outside the marking dots with sodium hyaluronate. d Making the initial hole and circumferential cutting: A hole was made outside the marking dots with GSF. One side of the GSF was inserted into the submucosa through the hole, and the mucosa was grasped, lifted up, coagulated shortly with soft coagulation mode, and cut with endo-cut mode. e Submucosal dissection: Submucosal dissection was performed with GSF in the same way. f Resected specimen: The specimen was pinned onto the Styrofoam plate for hisological assessment.

Article Snippet: Sodium hyaluronate (MucoUp; Johnson and Johnson, Tokyo, Japan) was used for submucosal injection.

Techniques: Coagulation, Injection, Dissection

Journal: Frontiers in Physiology

Article Title: Expression of Chitotriosidase in Macrophages Modulates Atherosclerotic Plaque Formation in Hyperlipidemic Mice

doi: 10.3389/fphys.2020.00714

Figure Lengend Snippet: (A) Cryosections of the aortic sinus from both CHIT1-OE mice and littermate controls after 12 weeks of HFD were stained with biotinylated antibodies against CHIT1. (B) Immunohistological staining for CHIT1 revealed significantly enhanced CHIT1 expression in the atherosclerotic plaques of CHIT1-OE mice when compared to control animals. Quantification represents stained area as a percentage of total plaque area ( P = 0.0101). (C) Serial cryosections of the aortic sinuswere also stained with MOMA to determine macrophage content. (D) Analysis of stained area versus % total plaque area. Measurement with ImageJ software showed no significant differences in macrophage content between experimental and control animals ( P = 0.1982). N = 7 per group, * P

Article Snippet: Visualization of hyaluronic acid was achieved using biotinylated hyaluronic acid binding protein (BHABP, EMD/Millipore/Calbiochem).

Techniques: Mouse Assay, Staining, Expressing, Software

Journal: Arthritis Research & Therapy

Article Title: Inhibition of hyaluronan export reduces collagen degradation in interleukin-1 treated cartilage

doi: 10.1186/ar2357

Figure Lengend Snippet: Influence of cGMP modulators. Shown is the influence of cGMP modulators on the hyaluronan (open bars), proteoglycan (solid bars), and collagen (cross-hatched bars) production of bovine cartilage. Cartilage explants were cultured in the presence of 2 ng/ml IL-1 and the guanylate cyclase inhibitor ODQ (1H-[1,2,4]-oxadiazolo [4,3a]quinoxaline-1-one; 25 μmol/l) or dibutyryl-cGMP (25 μmol/l). The incubation periods were for 3 days for hyaluronan, 5 days for proteoglycans and 28 days for collagens. For stimulation of collagen degradation, the cartilage explants were supplemented with 25 ng/ml IL-17, and 2 μmol/l retinoic acid. The concentrations of hyaluronan in the supernatant, proteoglycans and collagen (as hydroxyproline) were determined as described under Materials and methods. The error bars represent the standard deviation of three determinations.

Article Snippet: Vardenafil was from Bayer AG (Leverkusen, Germany), tadalafil was from Elli Lilly (Indianapolis, IA, USA), hyaluronan binding protein (HABP) was from Calbiochem (Schwalbach, Germany), and hyaluronan (Healon® ) was a gift from Genzyme (Cambridge, MA, USA).

Techniques: Cell Culture, Incubation, Standard Deviation

Journal: Arthritis Research & Therapy

Article Title: Inhibition of hyaluronan export reduces collagen degradation in interleukin-1 treated cartilage

doi: 10.1186/ar2357

Figure Lengend Snippet: Inhibition of hyaluronan export in bovine chondrocytes. (a) Cartilage explants were incubated in the absence and presence of IL-1α and the drugs tadalafil (○), zaprinast (□), or vardenafil (△). The concentration of hyaluronan was determined in the supernatant after 3 days. The error bars indicate the standard deviation of three determinations. (b) Effect of inhibitors on hyaluronan synthase activity. A particulate fraction of chondrocytes was prepared and incubated with the substrates UDP-GlcNac and UDP-[ 14 C]GlcA and increasing concentrations of tadalafil (○), zaprinast (□), or vardenafil (△), and the incorporation into [ 14 C]hyaluronan was determined.

Article Snippet: Vardenafil was from Bayer AG (Leverkusen, Germany), tadalafil was from Elli Lilly (Indianapolis, IA, USA), hyaluronan binding protein (HABP) was from Calbiochem (Schwalbach, Germany), and hyaluronan (Healon® ) was a gift from Genzyme (Cambridge, MA, USA).

Techniques: Inhibition, Incubation, Concentration Assay, Standard Deviation, Activity Assay

Journal: Eye

Article Title: Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome

doi: 10.1038/eye.2015.125

Figure Lengend Snippet: Change from baseline in the ocular surface markers after the substitution of 3% diquafosol ophthalmic solution for artificial tears and 0.1% sodium hyaluronate. The tear meniscus radius (a) was increased, and tear-film instability ((b)

Article Snippet: All subjects had been receiving instillation of an artificial tear solution (Soft Santear; Santen Pharmaceutical Co., Ltd., Osaka, Japan) 7 times daily (9 subjects) or 10 times daily (5 subjects), and 4 subjects additionally received 0.1% sodium hyaluronate (Hyalein; Santen Pharmaceutical) 6 times daily for more than 3 months prior to enrollment in this study.

Techniques:

Journal: Eye

Article Title: Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome

doi: 10.1038/eye.2015.125

Figure Lengend Snippet: Change from baseline in each subjective symptom after the substitution of 3% diquafosol ophthalmic solution for artificial tears and 0.1% sodium hyaluronate. Each graph shows the results of following symptoms; (a) dryness, (b) difficulty

Article Snippet: All subjects had been receiving instillation of an artificial tear solution (Soft Santear; Santen Pharmaceutical Co., Ltd., Osaka, Japan) 7 times daily (9 subjects) or 10 times daily (5 subjects), and 4 subjects additionally received 0.1% sodium hyaluronate (Hyalein; Santen Pharmaceutical) 6 times daily for more than 3 months prior to enrollment in this study.

Techniques:

Journal: International Medical Case Reports Journal

Article Title: Treatment with sodium hyaluronate eye drops in a patient who had early-onset bleb leakage after trabeculectomy with mitomycin C

doi: 10.2147/IMCRJ.S95334

Figure Lengend Snippet: ( A and B ) Photographs obtained 2 days after the initiation of sodium hyaluronate eye drops. Notes: The images show improvement of epithelial failure and resolution of the leakage point. Several microcysts are visible on the bleb surface at the sites where the epithelial failure showed improvement.

Article Snippet: On examination, severe keratoconjunctival epithelial failure ( ) was detected, and the patient was treated with 0.1% sodium hyaluronate eye drops (Hyalein; Santen Pharmaceutical Co Ltd, Osaka, Japan) administered six times daily with the patient lying supine to allow the drops to spread onto the upper blebs.

Techniques:

Journal: International Medical Case Reports Journal

Article Title: Treatment with sodium hyaluronate eye drops in a patient who had early-onset bleb leakage after trabeculectomy with mitomycin C

doi: 10.2147/IMCRJ.S95334

Figure Lengend Snippet: ( A and B ) Photograph taken 1 month after initiation of treatment with sodium hyaluronate eye drops. Note: The microcysts are absent and the bleb surface is smooth.

Article Snippet: On examination, severe keratoconjunctival epithelial failure ( ) was detected, and the patient was treated with 0.1% sodium hyaluronate eye drops (Hyalein; Santen Pharmaceutical Co Ltd, Osaka, Japan) administered six times daily with the patient lying supine to allow the drops to spread onto the upper blebs.

Techniques:

Journal: Therapeutic delivery

Article Title: Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head neck

doi: 10.4155/tde.10.38

Figure Lengend Snippet: Hyaluronan–Texas red to the surrounding lymphatics (24 h post-injection) Dashed circle and × indicate the location of the primary tumor and the nearby injection site, respectively. HNSCC: Head and neck squamous cell cancer.

Article Snippet: Hyaluronan (HA) from microbial fermentation was purchased from Lifecore Biomedical (MN, USA) as sodium hyaluronate and used without further purification.

Techniques: Injection

Journal: Therapeutic delivery

Article Title: Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head neck

doi: 10.4155/tde.10.38

Figure Lengend Snippet: Measurement of tumor size (A) Female animals were administered saline i.v., HA s.c., equivalent doses of CDDP i.v., HA–Pt s.c. and HA–Pt i.v. (3.5 mg/kg on Pt basis, 5 ≤ N ≤ 7). (B) Survival curves of female animals treated by saline, HA, CDDP or HA–Pt (5 ≤ N ≤ 7). (C) Lymphatic HA–Pt chemotherapy at 12 weeks. (D) Intravenous CDDP chemotherapy at 8 weeks. CDDP: Cisplatin; HA: Hyaluronan; HA–Pt: Hyaluronan–cisplatin; i.v.: Intravenous; s.c.: Subcutaneous.

Article Snippet: Hyaluronan (HA) from microbial fermentation was purchased from Lifecore Biomedical (MN, USA) as sodium hyaluronate and used without further purification.

Techniques:

Journal: Therapeutic delivery

Article Title: Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head neck

doi: 10.4155/tde.10.38

Figure Lengend Snippet: Measurements of tumor size and survival rate (A) Tumor size and (B) survival rate. Male animals were administered equivalent doses of CDDP i.v. and HA–Pt s.c. (3.5 mg/kg on Pt basis, N = 4 for CDDP i.v., N = 6 for HA–Pt s.c.) HA: Hyaluronan; HA–Pt: Hyaluronan–cisplatin; i.v.: Intravenous; s.c.: Subcutaneous.

Article Snippet: Hyaluronan (HA) from microbial fermentation was purchased from Lifecore Biomedical (MN, USA) as sodium hyaluronate and used without further purification.

Techniques:

Journal: Journal of Histochemistry and Cytochemistry

Article Title: Synthesis and Organization of Hyaluronan and Versican by Embryonic Stem Cells Undergoing Embryoid Body Differentiation

doi: 10.1369/jhc.2009.954826

Figure Lengend Snippet: Quantification of hyaluronan synthase (HAS) and versican gene expression. qRT-PCR was used to compare expression levels of HAS isoforms 1, 2, and 3 and versican splice variants V0, V1, V2, and V3 during the course of EB differentiation. HAS-2 increased

Article Snippet: Hyaluronan was quantified using a hyaluronan test kit (Corgenix; Denver, CO) by diluting the samples in 10 volumes of reaction buffer and adding 100 μl to hyaluronic acid binding protein (HABP)-coated microwells (1 hr, room temperature).

Techniques: Expressing, Quantitative RT-PCR

Journal: Journal of Histochemistry and Cytochemistry

Article Title: Synthesis and Organization of Hyaluronan and Versican by Embryonic Stem Cells Undergoing Embryoid Body Differentiation

doi: 10.1369/jhc.2009.954826

Figure Lengend Snippet: Quantification of hyaluronan synthesis by EBs. A quantitative hyaluronan (HA)-binding protein-based kit was used to measure hyaluronan retained within embryonic stem cells (ESCs) and day 4, 7, and 10 EBs ( A ) as well as hyaluronan secreted in medium conditioned

Article Snippet: Hyaluronan was quantified using a hyaluronan test kit (Corgenix; Denver, CO) by diluting the samples in 10 volumes of reaction buffer and adding 100 μl to hyaluronic acid binding protein (HABP)-coated microwells (1 hr, room temperature).

Techniques: Binding Assay

Journal: Journal of Histochemistry and Cytochemistry

Article Title: Synthesis and Organization of Hyaluronan and Versican by Embryonic Stem Cells Undergoing Embryoid Body Differentiation

doi: 10.1369/jhc.2009.954826

Figure Lengend Snippet: Hyaluronan accumulation during embryoid body (EB) formation. Sections (5 μm) from day 4, 7, and 10 EBs were stained with hyaluronan binding protein (dark red color); hematoxylin-stained nuclei are shown in blue. Hyaluronan was increasingly

Article Snippet: Hyaluronan was quantified using a hyaluronan test kit (Corgenix; Denver, CO) by diluting the samples in 10 volumes of reaction buffer and adding 100 μl to hyaluronic acid binding protein (HABP)-coated microwells (1 hr, room temperature).

Techniques: Staining, Binding Assay

Journal: Journal of Histochemistry and Cytochemistry

Article Title: Synthesis and Organization of Hyaluronan and Versican by Embryonic Stem Cells Undergoing Embryoid Body Differentiation

doi: 10.1369/jhc.2009.954826

Figure Lengend Snippet: Hyaluronan and versican spatial distributions. EBs were stained for both hyaluronan (green; A – C ) and versican isoforms V0 and V1 (red; D – F ); merged images show localization of the two molecules in yellow ( G –

Article Snippet: Hyaluronan was quantified using a hyaluronan test kit (Corgenix; Denver, CO) by diluting the samples in 10 volumes of reaction buffer and adding 100 μl to hyaluronic acid binding protein (HABP)-coated microwells (1 hr, room temperature).

Techniques: Staining

Journal: PLoS ONE

Article Title: Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

doi: 10.1371/journal.pone.0072030

Figure Lengend Snippet: Validation of hyaluronan and N-ERC/mesothelin levels as well as the two-step model. A) and B) Levels of hyaluronan and N-ERC/mesothelin, respectively, in the validation dataset. The dotted line represents cut-off values. C) Predicted risk values from the two-step predictive model. Cases with predicted risks > 0.9 were considered positive (above shaded area). D) ROC curves generated from N-ERC/mesothelin (solid black line) and hyaluronan (dotted black line) as single markers or combined in the two-step model (dotted grey line).

Article Snippet: The ELISA kit for hyaluronan was from Corgenix (ref. no. 029–001) and that for syndecan-1 from Diaclone (cat. no. 950.640.096).

Techniques: Generated

Journal: PLoS ONE

Article Title: Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

doi: 10.1371/journal.pone.0072030

Figure Lengend Snippet: Schematic representation and model calibration of both datasets. A) Schematic presentation of the two-step model and its performance on the model generation dataset. B) Schematic presentation of the two-step model and its performance on the validation dataset. In both A) and B) , after the logistic regression a predicted risk value > 0.9 indicates additional mesothelioma cases compared to hyaluronan or N-ERC/mesothelin alone. C) and D) Calibration plots showing the agreement between observed outcomes (y-axis) and predictions (x-axis) in the model generation dataset and validation dataset respectively.

Article Snippet: The ELISA kit for hyaluronan was from Corgenix (ref. no. 029–001) and that for syndecan-1 from Diaclone (cat. no. 950.640.096).

Techniques:

Journal: PLoS ONE

Article Title: Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

doi: 10.1371/journal.pone.0072030

Figure Lengend Snippet: Discrimination slopes between mesothelioma and non-mesothelioma for the different predictors in both datasets. Box plots of predicted probabilities using hyaluronan, N-ERC/mesothelin or the two-step model on the model generation dataset and validation dataset. The mean is denoted by a “+”, whiskers indicate the 5 th and 95 th percentiles, while dots are outliers. Grey dotted lines represent the discrimination slope (DS) which is equivalent to the integrated discrimination index. The differences in the discrimination slopes correspond to the integrated discrimination index [31] , [32] . As an example, the highest possible discrimination slope would be 1 (100%) and comparing N-ERC/mesothelin with the two-step model in the model generation dataset shows that the integrated discrimination index increases with 20% when applying the two-step model (DS Model 0.84 minus DS N-ERC 0.64).

Article Snippet: The ELISA kit for hyaluronan was from Corgenix (ref. no. 029–001) and that for syndecan-1 from Diaclone (cat. no. 950.640.096).

Techniques:

Journal: PLoS ONE

Article Title: Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

doi: 10.1371/journal.pone.0072030

Figure Lengend Snippet: Model generation and performance. A) ROC curves showing sensitivity and specificity for individual biomarkers. B) Predicted risk values from two-step model based on hyaluronan and N-ERC/mesothelin. Cases with a predicted risk > 0.9 were considered positive (above shaded area). C) ROC curve for the two-step model.

Article Snippet: The ELISA kit for hyaluronan was from Corgenix (ref. no. 029–001) and that for syndecan-1 from Diaclone (cat. no. 950.640.096).

Techniques:

Journal: PLoS ONE

Article Title: Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

doi: 10.1371/journal.pone.0072030

Figure Lengend Snippet: Biomarker expressions in diagnostic sub-groups in the model generation dataset. Levels of hyaluronan, N-ERC/mesothelin, C-ERC/mesothelin, osteopontin, syndecan-2, syndecan-1, and thioredoxin in patients with malignant pleural mesothelioma, other malignant pleural disease, or benign effusions. Values of 0 (i.e. below the detection limit) are tabulated for each group under the respective graph, as they cannot be shown on a logarithmic scale. Dotted line represents cut-off values. Horizontal lines represent medians. N tot /biomarker

Article Snippet: The ELISA kit for hyaluronan was from Corgenix (ref. no. 029–001) and that for syndecan-1 from Diaclone (cat. no. 950.640.096).

Techniques: Biomarker Assay, Diagnostic Assay

Journal: PLoS ONE

Article Title: Accumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness

doi: 10.1371/journal.pone.0193801

Figure Lengend Snippet: Effect of ECM composition and mechanical properties on growth-induced stress. ( A ) Collagen or ( B ) hyaluronan (HA) area fraction is not associated with growth-induced stress, whereas a relation seems to exist when ( C ) the ratio of HA/collagen area fraction is employed. ( D ) Growth-induced stress does not depend on tumor opening but there is a good correlation between growth-induced stress and tumor elastic modulus ( E ) as well as with the product of tumor opening and elastic modulus ( F ). Error bars represent the range of estimated growth-induced stress.

Article Snippet: Transverse 40μm-thick tumor sections were produced and immunostained with antibodies against collagen I (ab4710, Abcam), CD31 (MEC13.3, BD Biosciences) and hyaluronan (ab53842, Abcam), counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Labs).

Techniques:

Journal: PLoS ONE

Article Title: Accumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness

doi: 10.1371/journal.pone.0193801

Figure Lengend Snippet: Effect of ECM composition on tumor opening. ( A ) Collagen area fraction does not correlate with opening, whereas there is a correlation of tumor opening with hyaluronan (HA) area fraction ( B ) and the ratio of HA/collagen area fraction ( C ). Five tumor specimens (n = 5) from each tumor type were used.

Article Snippet: Transverse 40μm-thick tumor sections were produced and immunostained with antibodies against collagen I (ab4710, Abcam), CD31 (MEC13.3, BD Biosciences) and hyaluronan (ab53842, Abcam), counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Labs).

Techniques:

Journal: PLoS ONE

Article Title: Accumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness

doi: 10.1371/journal.pone.0193801

Figure Lengend Snippet: Experimental measurements and calculations for MCF10CA1a and 4T1 tumors. A : Tumor opening experimental data for the control and the two treated groups. B : Schematic of the tumor opening measurement, C : Area fraction quantification of collagen and hyaluronan (HA), D : Representative immunofluorescent images for collagen, HA and DAPI (scale bar:100μm). E : Elastic Modulus experimental data for the two tumors and the different groups employed. F : Schematic of mechanical measurements, high and low modulus is associated with stiffer and softer tumors, respectively, G : Growth-induced stress calculated using mathematical modeling, H . Error bars represent the standard error.

Article Snippet: Transverse 40μm-thick tumor sections were produced and immunostained with antibodies against collagen I (ab4710, Abcam), CD31 (MEC13.3, BD Biosciences) and hyaluronan (ab53842, Abcam), counterstained with 4',6-diamidino-2-phenylindole (DAPI, Vector Labs).

Techniques: